Dr. Rachel Tate
1 year ago
Can US differentiate pain? In #ACR23 Abs. #1388 PsA pts who have pain & inflammatory enthesitis on US, process pain differently than the US negative patients, despite the induction of pain or discomfort on all groups. Interesting finding. https://t.co/YcccLoQCBj @rheumnow https://t.co/o94bMwndxX
Aurelie Najm
1 year ago
Finally meeting @synovialjoints after 3 years of reporting together for @RheumNow!
Some serious interviews on AxSPA going on at the booth, I won’t reveal who was his guest: you’ll have to find out on https://t.co/YxAt6H2Qza https://t.co/dQHPw3pS3d
Robert B Chao, MD
1 year ago
What if you have a first degree relative with ankylosing spondylitis?
100 pts w/o previous rheum dx w/ 1st degree AS relative
17% had MRI sacroiliitis
25% met classification criteria
14% dx with AS
@RheumNow #ACR23 Abs#1403 https://t.co/Z0juhRnLki
Dr. Rachel Tate
1 year ago
15-year results from Abs #1389 at #ACR23 found only low back pain to be predictor of spinal radiographic progression in axSpA pts. Mean and median progression changes by mSASSS per year less in this cohort than previously documented. https://t.co/VKTEZWvH7f @rheumnow https://t.co/6sjPrcw2dD
Robert B Chao, MD
1 year ago
Biologics are working for ankylosing spondylitis, even in reducing cardiovascular mortality!
Large retrospective study of over 4k pts over 20 years showed decrease in CV mortality from 34% in 1999 to 21% in 2020
@RheumNow #ACR23 Abs#1399
#ACRbest https://t.co/wKCIXHza0v
Dr. Rachel Tate
1 year ago
Although general agreement that dz activity monitoring is important, implementation of AS/axSpA guideline recommendations is lacking. Guideline uptake & implementation should be considered in future updates of axSpA/AS tx recs. #ACR23 Abs #1385 https://t.co/RsyDppe3aR @rheumnow https://t.co/xxZ9pa77h9
Bella Mehta bella_mehta
1 year ago
Defining accuracy of Administrative Codes for Autoinflammatory Syndromes is important to lay groundwork!
AOSD, SJIA, BD, FMF, CAPS and SAPHO-CNO ICD codes validated as Autoinflammatory syndromes (AIS)- PPV low
@RheumNow #ACR23 #abst1129 https://t.co/XqIrUmUCVc
David Liew drdavidliew
1 year ago
Never forget the physical toll that RA has taken on our patients.
RA pts in BC🇨🇦, dx 1996-2008 (n=13367)
Fraility score 5y post-dx:
twice as likely to be frail vs matched controls
I would love to see those dx 2008-2018
Have biologics moved the needle?
#ACR23 ABST1275 @RheumNow https://t.co/gMXo5Pp1qA
Eric Dein
1 year ago
Upcoming Plenary II session
Ab#1584 on Bactrim for GPA pts on RTX
Should you use this for prophylaxis after weaning the prednisone?
#ACR23 @RheumNow
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Abstr#0509 Is sero-ve #Sjogren sero-ve? A study showed promising diagnostic model comprises clinical & novel autoantibodies (DTD2) using whole peptidome array (AUC:74%) to avoid need for lips biopsy in ANA-ve. Need further validation & wider access to this test @RheumNow https://t.co/FmE8AJdMVe
sheila
1 year ago
In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al)
⬆️freq AEs: nasopharyngitis & URTI
Low EAIRs/100pt yrs for IBD, malignancies & MACE
No new safety signals
Reassuring data.
#ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM
sheila
1 year ago
In their cohort, Dr. Jorge reports that SLE pts who used SGLT2i had⬇️risk of MACE(HR 0.69 [95% CI 0.48-0.99]) & renal progression(HR 0.71 [95% CI 0.51-0.98]) vs DPP4 use
Risk of MACE also⬇️in LN subgrp
🧐💊A potential role of SGLT2i for SLE/LN?
#ACR23 ABST1579 @RheumNow #ACRbest https://t.co/Dod8DqRvLo
Eric Dein
1 year ago
#ACR23 @RheumNow
SGLT2 inhibitors help CV & renal outcomes, but SLE pts excluded @AprilJorgeMD
ComparedSGLT2 to DPP4 inhibs, real world observation emulation study in SLE pts with T2DM
Lower incidence of MACE & renal progression
Subgroup w LN - risk reduction 10.2 MACE/100 py https://t.co/JpJ0yWNQBe
Robert B Chao, MD
1 year ago
Excellent start to Plenary II
Should we borrow SGLT2i and DPP4i use from endocrine?
SLE pts who initiated SGLT2 or DPP4: lower risk of MACE and renal progression
@RheumNow #ACR23 Abs#1579 https://t.co/RsaWuetyft
Aurelie Najm
1 year ago
RA peripheral blood mononuclear cells display IFN-gamma signature
Driven by 2 cell subsets: T cells & macrophages
IFNg driven transcription factors
Increased only in ACPA+ RA
Differential biology could inform ACPA stratified therapy
ABST1271 @RheumNow #ACR23 https://t.co/EN2noKGupK